Cargando…

Efficacy and tolerability of Meratrim for weight management: a randomized, double-blind, placebo-controlled study in healthy overweight human subjects

BACKGROUND: Meratrim is a blend of two plant extracts obtained from Sphaeranthus indicus flower heads and Garcinia mangostana fruit rinds. Previous studies have demonstrated that Meratrim is effective for weight management in obese individuals. The objective of this study was to assess the efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Kudiganti, Venkateshwarlu, Kodur, Raveendra Ramamurthy, Kodur, Sushma Raveendra, Halemane, Manjunath, Deep, Dheeraj Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4997756/
https://www.ncbi.nlm.nih.gov/pubmed/27558585
http://dx.doi.org/10.1186/s12944-016-0306-4
Descripción
Sumario:BACKGROUND: Meratrim is a blend of two plant extracts obtained from Sphaeranthus indicus flower heads and Garcinia mangostana fruit rinds. Previous studies have demonstrated that Meratrim is effective for weight management in obese individuals. The objective of this study was to assess the efficacy and tolerability of Meratrim in managing body weight in healthy overweight subjects. METHODS: Sixty participants with a mean BMI of 28.3 kg/m(2) were randomized into two groups receiving either 400 mg of Meratrim twice daily or two identical placebo capsules for a period of 16 weeks. Subjects were asked to consume about 2,000 kcal/day throughout the study period and walk 5 days a week for 30 min daily. The primary endpoint was defined as the change in body weight from baseline to end of week 16 for the Meratrim group versus placebo. Fifty seven subjects completed the trial. RESULTS: At study conclusion, statistically significant reductions in body weight (5.09 vs. 1.1 kg; p < 0.0001), BMI (1.91 vs. 0.43 kg/m(2); p < 0.0001), waist (9.97 vs. 3.71 cm; p < 0.001) and hip size (10.38 vs. 5.11 cm; p < 0.0001) were observed in the Meratrim versus the placebo group. Additionally, a significant change in serum LDL (−14.79 vs. 6.25 mg/dL; p < 0.0001), triglycerides (−43.62 vs. -13.68 mg/dL; p < 0.001) and total cholesterol (−20.0 vs. -0.75 mg/dL; p = 0.0002) was observed in the Meratrim cohort compared to the placebo. No supplementation related adverse events were noted during the study. CONCLUSIONS: The study findings suggest that Meratrim is well-tolerated and is an effective ingredient for weight management in healthy overweight subjects. TRIAL REGISTRATION: CTRI/2014/07/004727; www.CTRI.nic.in